Abstract: The epigenetic regulator Enhancer of Zeste Homolog 2 (EZH2) has emerged as a critical therapeutic target in various malignancies, including small cell lung cancer (SCLC), where its activity regulates transcriptional programs controlling differentiation and drug resistance. This review focuses on PF-06821497, a highly potent, orally bioavailable, and selective EZH2 inhibitor. Developed through rigorous ligand- and property-based design strategies, PF-06821497 overcomes the metabolic instability and poor thermodynamic solubility of earlier lactam-derived EZH2 inhibitors. By incorporating an sp3-hybridized oxetane ring, the compound achieves an optimal balance of lipophilic ligand efficiency, permeability, and metabolic stability. PF-06821497 demonstrates robust pharmacological activity, including profound tumor growth inhibition in xenograft models and synergistic apoptotic effects when combined with other therapeutic agents like ONC201. Currently in clinical trials for multiple cancers including SCLC, PF-06821497 represents a promising epigenetic therapeutic strategy.
1. Introduction
Polycomb group (PcG) proteins are essential regulators of heritable gene expression patterns, primarily functioning through the polycomb repressive complex 2 (PRC2). The PRC2 complex consists of core subunits including EED, SUZ12, and the catalytic subunit Enhancer of Zeste Homolog 2 (EZH2). EZH2 functions as a histone methyltransferase that catalyzes the mono-, di-, and tri-methylation of lysine 27 on histone H3 (H3K27me3), leading to the silencing of target genes involved in cell cycle, proliferation, and differentiation [1] [2]. Aberrant EZH2 activity and genetic alterations are recognized hallmarks of cancer, driving tumor initiation and progression in both hematological malignancies and solid tumors [1].
In the context of solid tumors, EZH2 activity has been shown to regulate transcriptional programs that control differentiation status and drug resistance in small cell lung cancer (SCLC) and neuroendocrine prostate cancer [1]. This provides a compelling rationale for the pharmacological inhibition of EZH2. PF-06821497 is a novel, orally bioavailable EZH2 inhibitor developed to address the metabolic and solubility liabilities of earlier lactam-based compounds. It is currently being evaluated in clinical trials for several indications, including small cell lung cancer, follicular lymphoma, castration-resistant prostate cancer, and diffuse large B-cell lymphoma (DLBCL) [2].
2. Pharmacological Activity
PF-06821497 exhibits potent and highly selective inhibition of EZH2, with a Ki of less than 0.1 nM for EZH2 and 70 nM for the closely related EZH1, while showing no significant inhibition against a broad panel of other methyltransferases, kinases, or cytochrome P450 isoforms [1]. In vitro, PF-06821497 effectively reduces global histone H3K27 methylation, leading to the de-repression of target gene transcription and subsequent anti-cancer effects [2].
In vivo, PF-06821497 demonstrates robust efficacy. In mice bearing Karpas-422 DLBCL tumor xenografts (which harbor the Y641N EZH2 mutation), twice-daily oral administration of PF-06821497 resulted in significant tumor growth inhibition at 100 mg/kg and profound tumor regression at 300 mg/kg, with minimal impact on animal body weight. Subcutaneous dosing further enhanced these regression outcomes, correlating strongly with significant reductions in tumor H3K27me3 levels [1].
Furthermore, PF-06821497 exhibits significant synergistic pharmacological activity when combined with other agents. It synergizes with the imipridone ONC201/TIC10 to suppress cell viability and induce apoptosis (evidenced by PARP and caspase 3 cleavage) across multiple cancer cell lines, including glioblastoma (GBM), diffuse midline glioma (DMG), colorectal adenocarcinoma, pancreatic cancer, and breast cancer [2].
3. Molecular Mechanism of Action
The primary mechanism of action of PF-06821497 involves binding to the EZH2 subunit within the tripartite PRC2 complex (EZH2/EED/SUZ12). Crystallographic studies reveal that the 4-methoxy-6-methylpyridone group of PF-06821497 forms critical hydrogen bond interactions with the backbone carbonyl and amide NH moieties of Trp624 in the EZH2 active site. This binding region normally accommodates a portion of the S-adenosyl-L-methionine (SAM) cofactor, which is essential for the methyl transfer reaction. By occupying this space, PF-06821497 disrupts the ability of SAM to associate with the protein, thereby impairing the enzyme's ability to methylate H3K27 [1].
In the context of combination therapies, the reduction of global histone H3K27 methylation by PF-06821497 mimics the epigenetic state of H3K27M-mutated cancers. This epigenetic modulation sensitizes tumor cells to ONC201, facilitating the activation of the integrated stress response (ISR). This response is characterized by the up-regulation of activating transcription factor-4 (ATF4) and the subsequent induction of the TRAIL death receptor DR5, ultimately driving the cells into caspase-dependent apoptosis [2].
4. Structure-Activity Relationship (SAR)
The development of PF-06821497 was driven by the need to overcome the poor human liver microsome (HLM) stability and low thermodynamic solubility of its predecessor, lead compound 1. SAR optimization utilized both ligand-based and physicochemical property-based design strategies [1].
A critical structural modification was the replacement of the planar dimethylisoxazole moiety with nonaromatic groups incorporating an sp3-hybridized carbon atom at the 7-position of the bicyclic lactam core. This shift out of "flatland" significantly improved thermodynamic solubility. Researchers discovered that targeting a calculated log D (clogD) range of 1.5 to 2.9 maximized the probability of simultaneously achieving favorable metabolic stability and in vitro permeability [1].
The introduction of an oxetane ring (as seen in PF-06821497) provided the optimal balance. The oxetane-methoxy group occupies the same spatial pocket as the previous dimethylisoxazole group, maintaining crucial contacts with the EZH2 protein, including a potential donor-π interaction between the polarized oxetane ring hydrogens and the EZH2 Tyr111 side chain. Furthermore, stereochemistry played a vital role; the (R)-enantiomer of PF-06821497 was significantly more potent because its conformation avoids allylic 1,3-strain, allowing the methine hydrogen to sit syn to the adjacent chloro group, which optimizes electrostatic interactions within the binding pocket [1].
5. Current Limitations
Despite the successful optimization of PF-06821497, the development process highlighted inherent challenges in balancing physicochemical properties. Alterations in lipophilicity often impacted in vitro parameters in opposing directions; for instance, modifications that increased log D to improve permeability frequently resulted in decreased metabolic stability [1]. Additionally, while PF-06821497 shows excellent synergy with ONC201 in many cell lines, the exact apoptotic mechanisms can be context-dependent. In certain cell lines (such as AGS gastric cancer cells), the combination therapy suppresses cell viability without inducing classic PARP cleavage or up-regulating the ATF4/DR5 axis, suggesting that alternative, currently uncharacterized survival or resistance mechanisms may be at play in specific genetic contexts [2].
6. Future Perspectives
The favorable preclinical profile of PF-06821497—characterized by high lipophilic ligand efficiency (LipE), excellent oral bioavailability, and robust in vivo efficacy—has supported its advancement into clinical development. Its ongoing evaluation in clinical trials for small cell lung cancer (SCLC) and other malignancies will be critical in determining its therapeutic utility in humans [1] [2].
Furthermore, the demonstrated synergy between PF-06821497 and other targeted agents, such as the ISR-activator ONC201 and histone deacetylase inhibitors (HDACi) like vorinostat, opens new avenues for rational combination therapies. By simultaneously targeting multiple epigenetic and stress-response pathways, these combinatorial regimens hold significant promise for overcoming drug resistance and improving clinical outcomes in difficult-to-treat cancers, including SCLC and pediatric gliomas [2].
